Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer

放射疗法可导致头颈癌中肿瘤抗原特异性淋巴细胞优先清除。

阅读:9
作者:Joseph Zenga ,Musaddiq J Awan ,Anne Frei ,Jamie Foeckler ,Rachel Kuehn ,Julia Kasprzak ,Becky Massey ,Jennifer Bruening ,Kenneth Akakpo ,Monica Shukla ,Stuart J Wong ,Angela J Mathison ,Jaime Wendt Andrae ,Bryan Hunt ,Andrii Puzyrenko ,Victor X Jin ,Abdullah A Memon ,Oscar Villarreal Espinosa ,Fanghong Chen ,Md Shaheduzzaman ,Tyce Kearl ,Peiman Hematti ,Heather A Himburg

Abstract

Human Papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with radiotherapy, alone or combined with immune checkpoint inhibitors, often failing to achieve durable disease control. Here, by conducting longitudinal multi-omic analyses of pre- and post-radiation biopsies from patients receiving a pre-operative hypofractionated radiation regimen, we uncover that radiation rapidly depletes a subpopulation of tumor-infiltrating lymphocytes (TIL), characterized by a proliferative, cytotoxic, and tissue-resident gene signature (TProlif_Tox). We provide multi-dimensional evidence for tumor antigen-specificity of TProlif_Tox clonotypes and show that post-radiation tumors are instead repopulated by regulatory and non-specific clones. Finally, TIL depletion correlates with radiorecurrent disease after conventional radiation, emphasizing the potential impact of radiation-induced TIL loss regardless of fractionation. Thus, this study provides key insights into radiotherapy-induced alterations in the immune microenvironment that drive immunologic radioresistance and proposes restoring tumor antigen-specific T cell clonotypes as a strategy to improve radioimmunotherapy responses in HNSCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。